SCHEMBL7215468

SCHEMBL7215468

CCCCCSc1nc2ccc(S(=O)(=O)N(Cc3ccccc3)[C@H](CO)C(N)=O)cc2s1

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PPARG P37231 4/20 0.42
PPARA Q07869 4/20 0.42
MAPT P10636 4/20 0.41
TP53 P04637 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
KDM4E B2RXH2 1/20 0.41
LMNA P02545 2/20 0.40
PPARD Q03181 2/20 0.40
ALOX5 P09917 1/20 0.39
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
ALDH1A1 P00352 1/20 0.38
GFER P55789 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5755663 0.89 PPARG (0.43) PPARGPPARAMAPTTP53SMN1; SMN2
SCHEMBL7221099 0.87 PPARG (0.42) PPARGPPARAMAPTTP53SMN1; SMN2
SCHEMBL5755047 0.87 MAPT (0.45) PPARGPPARAMAPTTP53SMN1; SMN2
SCHEMBL5758875 0.86 PPARG (0.43) PPARGPPARAMAPTTP53SMN1; SMN2
SCHEMBL5757620 0.86 MMP2 (0.50) PPARGPPARAMAPTTP53SMN1; SMN2
SCHEMBL5754680 0.86 MAPT (0.42) PPARGPPARAMAPTTP53SMN1; SMN2
SCHEMBL5753594 0.85 MMP2 (0.49) PPARGPPARAMAPTTP53SMN1; SMN2
SCHEMBL5760177 0.85 MMP2 (0.49) PPARGPPARAMAPTTP53SMN1; SMN2
SCHEMBL5756061 0.85 MMP2 (0.49) PPARGPPARAMAPTTP53SMN1; SMN2
SCHEMBL5757045 0.84 MMP13 (0.43) PPARGPPARAMAPTTP53SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6548667-B2 For prevention and treatment of diseases caused by overexpression and overactivation of matrix metalloproteinase SAMSUNG ELECTRONICS CO. LTD. (KR) 2003-04-15 US disclosed
US-20020169314-A1 Sulfonamide derivative as a matrix metalloproteinase inhibitor SAMSUNG ELECTRONICS CO. LTD. (KR) 2002-11-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020169314-A1 Sulfonamide derivative as a matrix metalloproteinase inhibitor MMP9, MMP3, MMP14 PPARG 3001/4885PPARA 2744/4885MAPT 4046/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.